01/07/2010 Hospital Vall d'Hebron Research Institute initiates major partnership in the field of novel biomarkers in rheumatoid arthritis 01/07/2010 Vall d'Hebron Research Institute (VHIR) and TcLand Expression have entered a strategic partnership on the development of new biomarkers for predicting the response to treatment in Rheumatoid Arthritis (RA). TcLand Expression will grant the exclusive and worldwide access to VHIR’s intellectual property covering biomarker predicting response to TNFa blockers in RA. Vall d'Hebron Research Institute (VHIR) and TcLand Expression have entered a strategic partnership on the development of new biomarkers for predicting the response to treatment in Rheumatoid Arthritis (RA). TcLand Expression will grant the exclusive and worldwide access to VHIR’s intellectual property covering biomarker predicting response to TNFa blockers in RA. Twitter LinkedIn Facebook Whatsapp
